Codexis, Inc. - Common Stock (CDXS)

After the closing bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

Codexis Inc (CDXS) beat Q2 2025 revenue and EPS estimates, driving a 6.89% after-hours stock surge. Strong enzyme engineering and RNAi therapeutic progress fuel optimism.

As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

CDXS stock results show that Codexis missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

CDXS stock results show that Codexis beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings.

Codexis, Inc. (NASDAQ: CDXS) entered a purchase deal with Nestlé S.A.(OTC: NSRGY) Nestlé Health Science for CDX-7108, a potential treatment for exocrine pancreatic insufficiency (EPI). 

Shares of Amtech Systems, Inc. (NASDAQ: ASYS) shares fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter sales results and issued first-quarter sales guidance below estimates.